Hypothesis Aging-associated microglial activation leads to secretion of exosomes enriched in miR-155, which are taken up by GnRH neurons and activate the IKKβ/NF-κB pathway, thereby suppressing GnRH transcription and driving systemic aging phenotypes.

Rationale

1. IKKβ/NF-κB signaling in hypothalamic neurons directly represses GnRH promoter activity (~50% inhibition) and its inhibition boosts GnRH release 4‑5 fold (1).
2. Transplantation of IκBα-engineered hypothalamic neural stem/progenitor cells (htNSCs) reverses aging phenotypes, partly via exosomal miRNA secretion (2).
3. Age‑dependent microglial priming is marked by upregulated MHCII, CD11b and pro‑inflammatory cytokines, while neuronal‑microglial communication via fractalkine/CX3CR1 and CD200 deteriorates (4).
4. Nutrient excess activates hypothalamic IKKβ/NF-κB, linking metabolic stress to inflammation (3).
5. Microglia release exosomes that transfer miR‑155 to neurons in other brain regions, where miR‑155 targets IκBα and potentiates NF‑κB activity (established in peripheral immune cells; we extend this to hypothalamus).
6. Astrocytic IKK2/NF-κB can drive microglial activation via paracrine signals, showing that glial‑to‑glial communication amplifies neuroinflammatory cascades (6).
7. The PI3K/Akt/FOXO3a axis can block IκBα phosphorylation and preserve GnRH promoter activity (5), providing a counter‑regulatory node that may be overwhelmed by microglial exosomal miR‑155.

Novel Mechanistic Insight We propose that microglial exosomes act as a paracrine conduit linking inflammatory microglial state to neuronal IKKβ/NF-κB activation. miR‑155 within these exosomes directly suppresses IκBα translation, removing the brake on NF‑κB, which then induces c‑Fos/c‑Jun and PKCα/PKCδ co‑repressors that bind the GnRH promoter. This creates a feed‑forward loop: reduced GnRH diminishes neuroprotective signaling, further activating microglia.

Testable Predictions

• In aged mice, hypothalamic microglia will show increased exosome release (measured by CD63+/TSG101+ particles) and higher miR‑155 content compared with young mice.
• GnRH neurons isolated from aged mice will exhibit elevated phospho‑IKKβ, phospho‑p65, and reduced IκBα protein levels; these changes will be attenuated by microglial depletion (e.g., CSF1R inhibitor) or by neutralizing exosome release (GW4869).
• Intracerebroventricular injection of synthetic miR‑155 mimics into young mice will recapitulate the aged phenotype: decreased GnRH mRNA, reduced LH pulses, and early onset of aging markers (e.g., htNSC loss, frailty).
• Conversely, antagomiR‑155 or overexpression of IκBα resistant to miR‑155 binding in GnRH neurons will prevent NF‑κB activation and preserve GnRH expression despite microglial priming.
• Transplantation of htNSCs engineered to secrete exosomes containing a miR‑155 sponge will rescue aging phenotypes more effectively than wild‑type htNSCs.

Experimental Approach

1. Isolate microglia from young (3 mo) and aged (24 mo) mice; quantify exosome yield and miR‑155 by qPCR and small‑RNA sequencing.
2. Co‑culture microglial exosomes with GT1‑7 GnRH‑expressing cells; assess IKKβ/NF‑κB phosphorylation, IκBα levels, and GnRH promoter luciferase activity.
3. In vivo, administer CSF1R inhibitor (PLX5622) or GW4869 to aged mice; measure hypothalamic GnRH transcription, serum LH, and aging phenotypes (body composition, cognition, htNSC density).
4. Use Cre‑dependent miR‑155 sponge or IκBα‑mutant constructs targeted to GnRH neurons (GnRH‑Cre) to test cell‑autonomous rescue.
5. Exosome tracking: label microglial exosomes with PKH67 and confirm uptake by GnRH neurons via confocal microscopy.

Potential Outcomes and Interpretation If microglial exosomal miR‑155 drives IKKβ/NF‑κB activation in GnRH neurons, then blocking this transfer should restore GnRH output and delay systemic aging. Failure to observe changes would suggest that microglial influence on GnRH is indirect or that other mediators dominate. Positive results would identify a novel neuroimmune axis that could be targeted by exosome‑based therapeutics or miRNA modulators to mitigate age‑related decline.